TrialAssure, Cancer Research UK team up on AI medical writing

Cancer Research UK’s Centre for Drug Development is using TrialAssure’s LINK AI to help draft regulatory and clinical trial documents for sponsored studies. The rollout could reduce manual work for medical writers as the charity expands its oncology pipeline and adds more complex trials. Why it matters: - Cancer Research UK’s Centre for Drug Development is trying to use generative AI to speed regulatory writing without removing human oversight. - The effort could help the team manage a growing portfolio of oncology studies, including complex trial types that create more document volume. - TrialAssure gains a high-profile life sciences partner as it pushes AI tools for regulated workflows. What happened: - TrialAssure and Cancer Research UK’s Centre for Drug Development announced a partnership to use TrialAssure LINK AI for regulatory and clinical trial document authoring. - Cancer Research UK’s Centre for Drug Development is using the tool to support medical writing in Cancer Research UK-sponsored studies. - The collaboration was announced June 18, 2026, in London. - The initial work focused on assessing LINK AI for regulatory document authoring workflows. - Cancer Research UK has started with the Investigator’s Brochure and plans to expand into Clinical Study Reports and patient narratives. The details: - The workflow is built around human-in-the-loop review, with medical writers reviewing, refining and finalizing AI-generated drafts. - Cancer Research UK worked with TrialAssure to align the out-of-the-box AI configuration with internal templates and instructional text. - LINK AI is being used to assist with content generation across a range of clinical and regulatory document types. - Amber Holmes, head of Quality, Regulatory, Pharmacovigilance and Medical Writing at Cancer Research UK’s Centre for Drug Development, said the partnership aims to streamline document authoring and free experts to focus on scientific content. - Holmes said the need is growing as the organization’s programs become more complex, including combination agents, multi-region submissions and precision medicine platform trials. - TrialAssure said the goal is to increase efficiency and reduce repetitive work while keeping experienced professionals in control of the authoring process. - TrialAssure said LINK AI is designed to fit existing workflows by adapting prompts to templates and letting medical writers shape each output. Between the lines: - The partnership reflects a cautious model for AI adoption in regulated drug development: automate the first draft, keep final judgment with subject-matter experts. - Cancer Research UK’s interest signals that AI tools are moving beyond experimentation and into operational use in regulatory writing. - TrialAssure is positioning LINK AI as a practical system for sponsors that need speed, but cannot compromise on compliance or review. What’s next: - Cancer Research UK will continue evaluating LINK AI in additional authoring workflows. - TrialAssure and Cancer Research UK are establishing a phased implementation path for broader use of the tool. - The collaboration will be watched for whether AI support can scale across more document types while maintaining quality and regulatory standards. The bottom line: - The deal is a sign that AI in life sciences is advancing from concept to day-to-day workflow support, with humans still making the final call.